Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma
New England Journal of Medicine · 31.07.2025 · 393 (5) · 425-437
DOI: 10.1056/nejmoa2505133 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 31.07.2025. Verfasst von Aurore Perrot und 26 weiteren Autor:innen. Beteiligte Einrichtung: Service Hématologie, Hôpital Universitaire de Toulouse Oncopole, Université de Toulouse, Toulouse, France. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Consolidation Chemotherapy, Hematopoietic Stem Cell Transplantation, Multiple Myeloma. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Service Hématologie, Hôpital Universitaire de Toulouse Oncopole, Université de Toulouse, Toulouse, France.
- Biostatistics and Medical Information Department, Hôpital St. Louis, Paris.
- Service d'Hématologie, Hôpital Haut Lévêque, Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France.
- Service Hématologie, Hôpital Universitaire de Dijon, Dijon, France.
- Service Hématologie, Hôpital Universitaire Lyon Sud, Pierre-Bénite, France.
- Hôpital Universitaire St. Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris.
ORCID-Profile: Aurore Perrot, Mohamad Mohty
Förderung
- NCI NIH HHS
Zitieren
APA
Perrot, A., Lambert, J., Hulin, C., Pieragostini, A., Karlin, L., Arnulf, B., Rey, P., Garderet, L., Macro, M., Escoffre-Barbe, M., Gay, J., Chalopin, T., Gounot, R., Schiano, J. M., Mohty, M., Leleu, X., Manier, S., Mariette, C., Chaleteix, C., …, & MIDAS Study Group (2025). Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma. New England Journal of Medicine, 393(5), 425-437. https://doi.org/10.1056/nejmoa2505133
Vancouver
Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, et al. Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma. New England Journal of Medicine. 2025;393(5):425-437. doi:10.1056/nejmoa2505133
BibTeX
@article{Perrot2025,
author = {Perrot, Aurore and Lambert, Jérôme and Hulin, Cyrille and Pieragostini, Andrea and Karlin, Lionel and Arnulf, Bertrand and Rey, Philippe and Garderet, Laurent and Macro, Margaret and Escoffre-Barbe, Martine and Gay, Julie and Chalopin, Thomas and Gounot, Romain and Schiano, Jean-Marc and Mohty, Mohamad and Leleu, Xavier and Manier, Salomon and Mariette, Clara and Chaleteix, Carine and Braun, Thorsten and De Prijck, Bernard and Avet-Loiseau, Hervé and Mary, Jean-Yves and Corre, Jill and Moreau, Philippe and Touzeau, Cyrille and MIDAS Study Group, MIDAS Study Group},
title = {Measurable Residual Disease–Guided Therapy in Newly Diagnosed Myeloma},
journal = {New England Journal of Medicine},
year = {2025},
volume = {393},
number = {5},
pages = {425--437},
doi = {10.1056/nejmoa2505133}
}
EUVIMED